Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet’s Syndrome

INTRODUCTION: To evaluate the efficacy of SB5, an adalimumab biosimilar, in the management of Behçet’s syndrome (BS)-related uveitis. METHODS: Data from eight BS patients (16 eyes) with active non-anterior uveitis and/or systemic uncontrolled disease or performing non-medical switch to SB5 were retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sota, Jurgen, Gentileschi, Stefano, Perfetti, Maria Orsetta, Frediani, Bruno, Tosi, Gian Marco, Cantarini, Luca, Fabiani, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589899/
https://www.ncbi.nlm.nih.gov/pubmed/34458968
http://dx.doi.org/10.1007/s40123-021-00387-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589899/
https://www.ncbi.nlm.nih.gov/pubmed/34458968
http://dx.doi.org/10.1007/s40123-021-00387-6

Ejemplares similares